---
title: "Abpro Holdings 10-K: $0 revenue, $(1.30) EPS on $2.89M net loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282902820.md"
description: "Abpro Holdings reported $0 revenue for the year, with a net loss of $2.892 million or $(1.30) per share. The operating loss was $(8.452) million, despite a 16% reduction in operating expenses. The company has substantial doubt about its ability to continue as a going concern, with only $0.067 million in cash. R&D services revenue ceased, and the company is pursuing equity financings and collaborations to resume development activities after being delisted from Nasdaq and now trading on OTC Pink."
datetime: "2026-04-15T21:35:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282902820.md)
  - [en](https://longbridge.com/en/news/282902820.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282902820.md)
---

# Abpro Holdings 10-K: $0 revenue, $(1.30) EPS on $2.89M net loss

Abpro Holdings reported zero revenue for the year as research and development services from Celltrion ceased, and posted a net loss of $2.892 million, or $(1.30) per share, reflecting improved results versus the prior year driven by non-operating income items. Operating loss was $(8.452) million amid a 16% reduction in operating expenses after R&D cutbacks and furloughs. Cash on hand was $0.067 million and management disclosed substantial doubt about the company's ability to continue as a going concern.

**Financial Highlights**

-   **Revenue:** $0 (R&D services revenue of $0.183M in 2024; no R&D services revenue in 2025)
-   **Loss from operations:** $(8.452) million
-   **Net loss:** $(2.892) million (improved from $(7.232) million in 2024)
-   **Net loss per share:** $(1.30) basic and diluted; weighted average shares 2.232 million (2024: $(22.31) on 0.780 million)
-   **Cash:** $0.067 million (cash and restricted cash $0.082 million)
-   **Going concern:** Management disclosed substantial doubt regarding ability to continue as a going concern

**Business Highlights**

-   **Pipeline progress:** Advanced two lead tetravalent antibody candidates, ABP-102 and ABP-201, targeting oncology and ophthalmology programs.
-   **Revenue shift:** No material product revenue in the period; R&D services revenue from Celltrion ceased in 2025, reducing total revenue to zero.
-   **Operational contraction:** R&D headcount was furloughed in October 2024 and largely terminated in Q4 2025, materially reducing R&D activity.
-   **Public markets and listing status:** Completed SPAC merger and PIPE financing in November 2024; subsequently delisted from Nasdaq in February 2026 and now trading on OTC Pink.
-   **Funding reliance and outlook:** Cash runway is constrained; company is pursuing equity financings, SEPA share issuances, and collaborations to resume development activities.

Original SEC Filing: Abpro Holdings, Inc. \[ ABPO \] - 10-K - Apr. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ABPO.US](https://longbridge.com/en/quote/ABPO.US.md)
- [ABPWW.US](https://longbridge.com/en/quote/ABPWW.US.md)
- [ABP.US](https://longbridge.com/en/quote/ABP.US.md)